Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal
electroretinography (mf-ERG).
Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and
retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients
underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography
and mf-ERG before and 1 month after treatment.